Mechanism of action of sotoracib (AMG510) in the treatment of lung cancer

Sotoracib (AMG510) is a tumor-targeted therapy drug commonly used to treat non-small cell lung cancer. Its mechanism of action mainly involves targeting key signaling pathways that inhibit the growth and spread of cancer cells.

1.EGFRInhibition: Sotoraxib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is an important cell surface receptor that is often overexpressed in tumor cells. It is involved in key biological processes such as cell proliferation, survival and metastasis. Sotorasiib can bind to EGFR and block its signal transduction, thereby inhibiting the growth and spread of tumor cells.

2.PDGFRInhibition: In addition to EGFR, sotoraxib can also inhibit another receptor related to angiogenesis——vascular endothelial growth factor receptor (PDGFR). PDGFRPlays an important role in tumor angiogenesis. Its inhibition can reduce the vascular supply of tumors, thereby blocking the nutrient supply of tumors and inhibiting their growth.

3.Tumor angiogenesis inhibition: Sotoraxib can further inhibit tumor growth by inhibiting tumor angiogenesis. Angiogenesis is one of the necessary conditions for tumor growth and metastasis, and sotorasiib interferes with the formation of tumor blood vessels by inhibiting vascular endothelial growth factor receptor (VEGFR) and other related pathways, reducing the blood supply of tumors, making it difficult for tumor cells to obtain sufficient oxygen and nutrients, thus inhibiting tumor growth.

In summary, sotorasiib targets and interferes with key biological processes such as tumor cell growth, angiogenesis and metastasis through multiple pathways, thereby effectively inhibiting the development and progression of lung cancer. However, it is worth noting that the use of sotorasiib may be accompanied by some side effects, such as rash, diarrhea, fatigue, etc., so close monitoring and timely treatment are required during use.